Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial

2020 ◽  
Vol 5 (2) ◽  
pp. 142-151 ◽  
Author(s):  
Hitoshi Katai ◽  
Junki Mizusawa ◽  
Hiroshi Katayama ◽  
Shinji Morita ◽  
Takanobu Yamada ◽  
...  
Keyword(s):  
Distal Gastrectomy ◽  
Controlled Trial ◽  
Clinical Stage ◽  
Survival Outcomes ◽  
Open Distal Gastrectomy ◽  
Phase 3 ◽  
Clinical Stage Ia ◽  
Nodal Dissection ◽  
Stage Ia ◽  
Randomised Controlled

scholarly journals Early phase II study of robot-assisted distal gastrectomy with nodal dissection for clinical stage IA gastric cancer

2013 ◽  
Vol 17 (3) ◽  
pp. 542-547 ◽  
Author(s):  
Masanori Tokunaga ◽  
Norihiko Sugisawa ◽  
Junya Kondo ◽  
Yutaka Tanizawa ◽  
Etsuro Bando ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Early Phase ◽  
Distal Gastrectomy ◽  
Phase Ii Study ◽  
Clinical Stage ◽  
Robot Assisted ◽  
Clinical Stage Ia ◽  
Nodal Dissection ◽  
Stage Ia

Morbidity and mortality after laparoscopy-assisted and open distal gastrectomy for stage I gastric cancer: Results from a multicenter randomized controlled trial (KLASS-01).

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 4-4 ◽  
Author(s):  
Hyuk-Joon Lee ◽  
Hyung-Ho Kim ◽  
Sang Uk Han ◽  
Min-Chan Kim ◽  
Woo Jin Hyung ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Randomized Controlled Trial ◽  
Distal Gastrectomy ◽  
Controlled Trial ◽  
Clinical Stage ◽  
Wound Complication ◽  
Stage I ◽  
Open Distal Gastrectomy ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial

4 Background: Laparoscopy assisted distal gastrectomy (LADG) is widely performed for gastric cancer in Eastern countries, although large scale prospective data are still lacking. We conducted a phase III, multicenter randomized controlled trial (KLASS-01) to compare the short and long term outcomes of LADG versus open distal gastrectomy (ODG) in patients with clinical stage I gastric cancer in Korea. Methods: The primary end point was 5-year overall survival. The morbidity within 30 postoperative days and the surgical mortality were compared to evaluate the safety of LADG as a secondary end point. A total of 1,416 patients were randomly assigned to the LADG group (n = 705) or the ODG group (n = 711) between Feb 1, 2006 and Aug 31, 2010. Results: 1,256 were eligible for per protocol (PP) analysis (644 and 612, respectively). The overall complication rate was significantly lower in the LADG group (LADG vs. ODG; 13.0% vs. 19.9%, P =.001). In detail, the wound complication rate of the LADG group was significantly lower than that of the ODG group (3.1% vs. 7.7%, P <.001). The major intra-abdominal complication (7.6% vs. 10.3%, P =.095) and mortality rates (0.6% vs. 0.3%, P =.450) were similar between groups. Modified intention-to-treat analysis showed similar results with PP analysis. Conclusions: LADG for patients with clinical stage I gastric cancer is safe and has a benefit of lower occurrence of wound complication compared with conventional ODG. Clinical trial information: NCT00452751.

Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 4020-4020 ◽  
Author(s):  
Hitoshi Katai ◽  
Junki Mizusawa ◽  
Hiroshi Katayama ◽  
Shinji Morita ◽  
Takanobu Yamada ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Primary Endpoint ◽  
Treatment Guidelines ◽  
Distal Gastrectomy ◽  
Clinical Stage ◽  
Stage I ◽  
Phase Iii ◽  
Open Distal Gastrectomy ◽  
Number Of Patients ◽  
Nodal Dissection

4020 Background: The number of patients undergoing laparoscopy-assisted distal gastrectomy (LADG) has been increasing worldwide. Several retrospective studies have demonstrated equivalent survival after LADG compared to open distal gastrectomy (ODG). However, no confirmatory randomized controlled trials has been published in a peer review journal to evaluate the efficacy of LADG compared with ODG, ensuring strict surgical skill and quality control of surgery. We conducted phase III study to confirm that LADG is not inferior to ODG in efficacy. Methods: Eligibility criteria included histologically proven adenocarcinoma in the middle or lower third of the stomach; clinical stage I tumor (T1N0, T1N1, T2(MP)N0). Patients were preoperatively randomized to ODG or LADG. LADG was performed by accredited surgeon. The extent of nodal dissection was decided according to Japanese gastric cancer treatment guidelines. The primary endpoint is relapse-free survival (RFS) and the secondary endpoints are overall survival (OS), short-term clinical outcomes, and postoperative quality of life. Planned sample size was 920 patients in total, which was determined with at least 80% power, a one-sided alpha of 5%, and a non-inferiority margin for a hazard ratio of 1.54. Before the 1st interim analysis, the primary endpoint was amended from OS to RFS in 2015 because the surrogacy of RFS for OS was demonstrated and the predicted number of events for OS was smaller than expected. Results: A total of 921 patients were randomized (ODG 459, LADG 462) between Mar. 2010 and Nov. 2013. Among 921 patients, 912 patients (99%) underwent assigned surgery. Conversion to ODG was needed for 16 patients (3.5%) in LADG arm mainly due to advanced disease. 5-year RFS was 94.0% (95% CI: 91.4-95.9%) in ODG and 95.1% (92.7-96.8%) in LADG. LADG was non-inferior to ODG for RFS. (HR: 0.84 [90% CI: 0.56-1.27 ( < 1.54)], p for non-inferiority = 0.008). 5-year OS was 95.2% (92.7-96.8) in ODG and 97.0% (94.9-98.2) in LADG (HR: 0.83 [95% CI: 0.49-1.40]). Conclusions: The non-inferiority of LADG to ODG in RFS was confirmed. LADG has been established as one of the standard treatments for clinical stage I gastric cancer. Clinical trial information: UMIN000003319.

Sign in / Sign up

Export Citation Format

Share Document